+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07383025

Post-marketing Study of Mavacamten Treatment in Adults With Obstructive Hypertrophic Cardiomyopathy in Japan

Led by Bristol-Myers Squibb · Updated on 2026-02-03

200

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are assessing the real-world use and safety of mavacamten in adults with obstructive hypertrophic cardiomyopathy oHCM who are receiving this treatment in Japan. This study focuses on patients starting mavacamten as approved for their condition and aims to collect information on how the drug performs outside of clinical trials. Participants in this observational study will receive mavacamten according to the approved product label, without additional experimental interventions. The study involves patients who initiate treatment during the enrollment period at medical institutions in Japan. During the study, researchers will monitor and record any adverse events or serious adverse events for up to 52 weeks. They will also document any actions taken after such events and their outcomes. This approach helps understand the safety profile of mavacamten in routine clinical practice over about one year of follow-up.

CONDITIONS

Brief Title

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Research Team

B

BMS Study Connect Contact Center www.BMSStudyConnect.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here